Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 9/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3761529 | 0.90 | CNR2 (0.55) | KMT2AMEN1RAB9ACNR2EPHX2 | |
| SCHEMBL3764773 | 0.89 | CNR2 (0.53) | KMT2AMEN1RAB9ACNR2EPHX2 | |
| SCHEMBL3767375 | 0.88 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL3761428 | 0.87 | CNR2 (0.53) | KMT2AMEN1RAB9ACNR2CNR1 | |
| SCHEMBL3767621 | 0.87 | CNR2 (0.55) | KMT2AMEN1RAB9ACNR2CNR1 | |
| SCHEMBL3758985 | 0.84 | CNR2 (0.52) | CNR2CNR1 | |
| SCHEMBL3764717 | 0.81 | CNR2 (0.56) | CNR2CNR1 | |
| SCHEMBL3765716 | 0.81 | CNR2 (0.56) | KMT2ACNR2LMNACNR1 | |
| SCHEMBL3766478 | 0.80 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL3767415 | 0.80 | CNR2 (0.56) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | claimed |
| EP-2035409-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANATGONIST FOR THE CB1-RECEPTOR | AstraZeneca AB (SE) | 2009-03-18 | — | — | EP | claimed |
| WO-2007145563-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | claimed |
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2010-12-02 | — | — | US | disclosed |
| WO-2007145563-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | ASTRAZENECA AB (SE) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305140-A1 | BENZIMIDAZOLE DERIVATIVES WHICH ARE TO BE USED AS ANTAGONIST FOR THE CB1-RECEPTOR | CNR1, CNR2, CCKAR | KMT2A 1825/4885MEN1 3805/4885RAB9A 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.